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Abstract
Background: Deleted in Liver Cancer 1 (Dlc1) is a tumor suppressor gene, which maps to human chromosome
8p21-22 and is found frequently deleted in many cancers including breast cancer. The promoter of the remaining
allele is often found methylated. The Dlc1 gene encodes a RhoGAP protein that regulates cell proliferation,
migration and inhibits cell growth and invasion when restored in Dlc1 deficient tumor cell lines. This study focuses
on determining the role of Dlc1 in normal mammary gland development and epithelial cell polarity in a Dlc1 gene
trapped (gt) mouse.
Methods: Mammary gland whole mount preparations from 10-week virgin heterozygous Dlc1gt/+ gene-trapped
mice were compared with age-matched wild type (WT) controls. Hematoxylin-Eosin (H&E) and Masson’s Trichrome
staining of histological sections were carried out. Mammary glands from Dlc1gt/+ mice and WT controls were
enzymatically digested with collagenase and dispase and then cultured overnight to deplete hematopoietic and
endothelial cells. The single cell suspensions were then cultured in Matrigel for 12 days. To knockdown Dlc1
expression, primary WT mammary epithelial cells were infected with short hairpin (sh) RNA expressing lentivirus or
with a scrambled shRNA control.
Results: Dlc1gt/+ mice showed anomalies in the mammary gland that included increased ductal branching and
deformities in terminal end buds and branch points. Compared to the WT controls, Masson’s Trichrome staining
showed a thickened stromal layer with increased collagen deposition in mammary glands from Dlc1gt/+ mice.
Dlc1gt/+ primary mammary epithelial cells formed increased solid acinar spheres in contrast with WT and scrambled
shRNA control cells, which mostly formed hollow acinar structures when plated in 3D Matrigel cultures. These solid
acinar structures were similar to the acinar structures formed when Dlc1 gene expression was knocked down in WT
mammary cells by shRNA lentiviral transduction. The solid acinar structures were not due to a defect in apoptosis
as determined by a lack of detectible cleaved caspase 3 antibody staining. Primary mammary cells from Dlc1gt/+
mice showed increased RhoA activity compared with WT cells.
Conclusions: The results illustrate that decreased Dlc1 expression can disrupt the normal cell polarization and
mammary ductal branching. Altogether this study suggests that Dlc1 plays a role in maintaining normal mammary
epithelial cell polarity and that Dlc1 is haploinsufficient.
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Background
Breast tumors undergo frequent gene copy number
changes [1, 2]. One chromosomal region, 8p22, shows
frequent copy number loss in 16–20 % of breast cancers,
without a loss of heterozygosity, suggesting the location
of a haploinsufficient tumor suppressor gene(s) (ibid.).
The Deleted in Liver Cancer-1 (Dlc1) tumor suppressor
gene maps to this chromosomal region (for review see
[3]). The Dlc1 gene was initially found associated with
frequent deletions in hepatocellular carcinomas [4].
Using tiling microarrays, Xue et al. showed that hetero-
zygous deletion of Dlc1 occurred in approximately 50 %
of breast, liver, pancreatic and lung tumors and more
than 70 % of colon cancers [5]. Although these deletions
could be up to five Mbps (~20 genes), they always in-
cluded the Dlc1 locus (ibid.). The promoter of the
remaining allele of Dlc1 is also frequently found hyper-
methylated in many cancer types [6]. Chromosome re-
gion 8p22 contains several tumor suppressor genes that
may cooperate with Dlc1 loss to increase tumor aggres-
siveness [7]. Reduced or absent expression of Dlc1 has
been frequently found in primary breast tumors and cell
lines [8, 9]. Transfection of Dlc1 into deficient breast
tumor cells will inhibit both in vitro and in vivo tumor
cell growth [9, 10]. Another study, using matched malig-
nant and nonmalignant human breast cancer cell lines,
showed that the nonmalignant line had Dlc1 transcript
levels 3-fold greater than the malignant clone [11]. Over-
all these results suggest that Dlc1 may be an important
tumor suppressor in breast cancer.
The Dlc1 protein shows homology with the rat
p122RhoGAP protein, which was initially found as a bind-
ing partner of Phospholipase C-delta 1 (PLC-δ1), stimu-
lating its activity [12]. The Dlc1 RhoGAP protein has
three structural regions namely; an amino terminal
SAM2 (sterile α motif ), a Rho GTPase activating protein
(RhoGAP) and a StAR related lipid transfer (START) do-
mains [3]. Dlc1 protein shows strong Gap activity for
RhoA, B and C [12–14]. The Dlc1 protein has been lo-
calized to caveolae and binds to caveolin 1 [15–17].
Also, the Dlc1 protein has been found in focal adhesions
binding to adhesion proteins vinculin [18] and tensin
[19–21]. Dlc1 has also been found to bind FAK (focal
adhesion kinase) and talin with this binding region being
needed for its full tumor suppressor activity in vitro [22].
This region when mutated does not interfere with Dlc1’s
RhoGAP activity, indicating that signalling pathways
other than Rho may also be needed for its tumor sup-
pressor activity (ibid.).
Postnatally the mouse mammary gland develops through
branching morphogenesis to form a treelike ductal system
that penetrates into the stromal fat pad followed by alveo-
logenesis during pregnancy (for review see [23]). The key
structure driving this process is the terminal end bud
(TEB) where epithelial precursors grow and differentiate
into luminal and myoepithelial cell compartments forming
the bilayered duct [24]. As in all epithelial tissues, the es-
tablishment of polarity by epithelial cells is critical for
proper lumen and ductal formation influenced by interac-
tions with the extracellular matrix and cell-cell adhesions
[25]. Mammary epithelial cell polarity can be modelled in
vitro by culturing cells in a laminin-rich extracellular
matrix (Matrigel), which allows formation of hollow
spherical acinar structures [26]. The loss of this cell polar-
ity is a characteristic feature of advanced epithelial tumors
and may play an important role in their initiation and pro-
gression [27].
The Rho GTPases play critical roles in the formation
and maintenance of epithelial cell adhesion structures
[28]. Several studies have shown the importance of Rho
signalling in mammary gland development. Heterozy-
gous loss of the p190B RhoGAP gene results in delayed
ductal growth, due to reduced terminal cap cell layer
proliferation compared with wild type mice [29]. Trans-
plantation of homozygous p190B-/- mammary anlagen
resulted in no ductal outgrowth (ibid.). The closely re-
lated p190A RhoGAP also shows halpoinsufficiency,
with a slight delay of ductal outgrowth and a disrupted
TEB architecture [30]. Tissue transplants showed that
p190A was needed in both the epithelial and stromal cell
layers for ductal outgrowth, although the phenotype was
less severe than p190B deficiency (ibid.). Constitutive ex-
pression of Vav2, a guanine nucleotide exchange factor for
Cdc42 and Rac1, results in disruption of the acinar archi-
tecture in mammary cell line 3D cultures [31]. In contrast,
RhoA activation was associated with stability of acinar
structures and E-cadherin cell-cell adhesions (ibid.).
To understand the role that Dlc1 loss plays in breast
cancer, it is important to understand its role in normal
mammary morphogenesis. Also, since Rho signalling is
important for mammary gland morphogenesis, we wanted
to learn if Dlc1 played a role in mouse mammary ductal
development. To carry out these experiments, we made
use of a gene trapped (gt) Dlc1 mouse that was hypo-
morphic for Dlc1 isoform 2 expression [32]. This mouse
shows embryonic lethality when homozygous, but appears
“normal” when heterozygous (ibid.). In the present study,
we showed that these heterozygous Dlc1gt/+ mice exhib-
ited anomalies in mammary gland with increased ductal
branching and irregularity in the branch points/terminal
end buds. The normal polarization and lumen formation
that occurs during epithelial cell morphogenesis in 3D aci-
nar cultures were also affected as a result of heterozygous
loss of Dlc1. Knockdown of Dlc1 expression in wild type
cells showed a similar loss of polarity. These results sug-
gest that Dlc1 plays a role in maintaining normal mam-
mary epithelial cell polarity and also is haploinsufficient
for mammary ductal development.
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Methods
Animals
The generation of the Dlc1 gene trapped mutant mice
(Dlc1Gt(XE082)Byg/+) were previously described [32]. The
Dlc-1gt/+ mice were backcrossed to C57Bl/6 mice for at
least 7 generations before experiments were carried out.
Animal ethics
All experiments were performed as per the Canadian
Council on Animal Care (CCAC) and were affirmed by
the University of Manitoba Animal Protocol Manage-
ment and Review Committee before experimentation.
Whole mount preparation of mammary gland
For the whole gland morphological analysis, the fourth
inguinal mammary glands were surgically removed from
10 week old heterozygous Dlc1gt/+ gene trapped and
wild type virgin female mice. The whole mounts of
mammary glands were prepared as previously described
[33]. Briefly, mammary glands were fixed in 4 % parafor-
maldehyde, defatted in acetone, dehydrated in ethanol,
followed by staining with 0.2 % carmine alum overnight.
The whole mounts were then destained, ethanol dehy-
drated and finally cleared in xylene. The whole mounts
were analyzed by light microscopy for various parame-
ters including branching morphogenesis, number of
TEBs or branch points and branching density. Individual
whole mount glands were divided into two regions,
proximal and distal relative to the lymph node, for
counting the TEBs for each region and summed to ob-
tain the total number of TEBs/individual mammary
gland. Abnormal or defective TEBs were defined as TEBs
that were trifurcated or had multiple buds on the neck.
The thickening of the ductal branches in the mammary
glands was determined using the measuring tool in
Adobe Acrobat X Pro.
Immunofluorescent staining of mouse mammary glands
Paraffin embedded histological sections of mouse mam-
mary glands were used for immunofluorescence staining.
The slides were deparaffinised and hydrated by washing
with xylene (twice), 100 % EtOH, 90 % EtOH, 70 %
EtOH and water for 5 mins. Antigen retrieval was car-
ried out by boiling the slides for 15–20 min in citrate
buffer and allowed to cool at room temperature for
15 min. After incubation in water the slides were perme-
abilized with 0.5 % Triton X-100. After two PBS washes,
sections were blocked with 10 % goat serum for 2 h.
Then primary antibody was added to the slides and
incubated overnight at 4 °C in a humidified chamber.
Primary antibodies used were cytokeratin 18 (Abcam, at
1:300 dilution), and cytokeratin 14 (Covance, CA; 1:400),
cleaved caspase -3 (Cell Signaling Technology, 1:200),
Ki67 (Abcam, 1:200). The expression of each protein
was detected using either FITC, PE or Cy3 conjugated
secondary antibodies (at 1:300 dilution). DAPI (Sigma,
USA) or Topro-3 (5 μM, Molecular Probes, Eugene, OR)
were used to stain the nculeus.
Dissociation and preparation of mammary single cell
suspensions
For the preparation of mammary single cell suspen-
sions, fourth inguinal mammary glands from 10 week
old virgin WT or Dlc1gt/+ mice were surgically re-
moved and mechanically chopped followed by enzym-
atic dissociation with collagenase (US Biologicals,
Swampscott, MA) and dispase (Life Technologies,
Burlington ON) for 2–3 h at 37 °C as described [34].
Briefly, the digested suspensions were pelleted, resus-
pended in 1 mM EDTA-PBS buffer and the number
of viable cells determined by automated cell counter
(Bio-Rad TC10) according to the manufacturer’s in-
structions. Dissociated mammary epithelial cells were
cultured overnight with mammary epithelial growth
media, (MEGM; Dulbecco’s Modified Eagle media
(Gibco), 5 μg/mL insulin (Sigma), 1 μg/mL hydrocor-
tisone (Sigma), 10 ng/mL epidermal growth factor
(EGF; BD Biosciences), 1× Penicillin/Streptomycin (P/S;
Life Technologies), 35 μg/ml bovine pituitary extract
(BD Bioscience, San Jose, CA)] supplemented with
5 % FBS (BD Biosciences, San Jose, CA) in 6-well
plates to allow depletion of hematological and endo-
thelial cells.
3D Matrigel culture of the mammary epithelial cells
Adherent mammary single cells obtained after overnight
culture were then trypsinized and counted. Approxi-
mately 2 × 105 viable cells were placed in 8-well chamber
slides containing growth factor reduced Matrigel (Corning,
VWR Edmonton, AB) with cell culture media consist-
ing of MEGM supplemented with 2 % FBS as de-
scribed [33, 34]. The media was changed every 2–3
days and maintained for 10–12 days at which point
the acinar structures were fixed, permeabilized and
stained as described below.
Histological analyses
For histological analyses, the fourth inguinal mammary
glands from 10 week old virgin WT or Dlc1gt/+ mice
were surgically removed and fixed overnight at 4 °C with
phosphate-buffered 4 % paraformaldehyde. Paraffin em-
bedding, sectioning, H&E and Trichrome staining were
performed by the Manitoba Tumor Bank Histology Core
Facility (CancerCare Manitoba). Thereafter, H&E and
Trichrome stained sections were analysed and imaged
on the EVOS XL cell imaging system (Life Technologies)
according to the manufacturer’s instructions.
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Short Hairpin RNA (shRNA) lentiviral transduction
Primary mammary epithelial cells from 10 week old WT
virgin mice were infected with a pool of lentivirus produced
from two pGIPZ-puro shRNA expression vectors targeting
Dlc1 (Thermo Fisher, St Louis, MO), as previously de-
scribed [35]. For the knockdown experiments, a pGIPZ-
puro shRNA scrambled control was also used. The infected
cells were selected with 1.5 μg/ml puromycin 2 days after
infection. To obtain cells containing stably integrated
shRNA, the puromycin selection was continued for at least
2 weeks. Lentiviral packaging plasmids pCMV-dR8.2
and pCMV-VSVG (Addgene plasmids #8455 for
pCMV-dR8.2 and #8454 for pCMV-VSVG) were used
to co-transfect with each plasmid into HEK 293T
cells for virus production [36]. The viral supernatant
was concentrated by ultracentrifugation and lentivirus
transduction was performed using a multiplicity of infec-
tion (MOI) of approximately 10.
RNA isolation and RT-qPCR analysis
RNA was extracted from puromycin selected lentivirus
infected mammary epithelial cells using Trizol (Life
Technologies, Burlington, ON) according to the manu-
facturer’s protocol. Biorad CFX real-time PCR system
was used to determine the relative mRNA expression
levels using the ΔCT method and all values were nor-
malized to GAPDH expression. Sequence of primers
used; GAPDH forward 5′-GCACAGTCAAGGCCGA
GAAT-3′, reverse 5′-GCCTTCTCCATGGTGGTGAA-3′;
Dlc1 forward 5′-CGGTTGTTGCTAGAGCCTTG-3′, re-
verse 5′- ACCTAAGACAGACAGGAAGCAG-3′.
Fig. 1 Increased mammary terminal end buds/branch points in Dlc1gt/+ mice. a–d Representative images of fourth inguinal mammary gland
whole mounts of 10 week old virgin wild type mice (a & c) and Dlc1gt/+ gene-trapped mice (b & d) on C57BL/6 background. Red arrowhead
indicates terminal end buds (TEBs). Scale bar, 2 mm. e Bar graph showing that the total number of TEBs in 10 week old Dlc1gt/+ compared to the
wild type mammary glands. Data represents the mean ± SD of 5 different glands (N = 5) from 5 different mice for each group. f Quantification of
the number of TEBs in the distal and proximal regions relative to the central lymph node. Data represents the mean ± SD. A total number of 5
different glands from 5 different mice were studied for each group by two-tailed Student’s t test, *p < 0.05. ns-not significant
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Western blot analysis
Total proteins were extracted from primary mammary
epithelial cells of Dlc1gt/+ and WT mice and 70 μg of ly-
sates were separated by SDS-PAGE. The proteins were
then transferred to Immobilon-P PVDF (polyvinylidene
difluoride) membrane (Millipore, ON] for determination
of specific protein expression levels using anti-rabbit Dlc1
(Santa Cruz Biotechnology, Dallas, TX,1:1000, cat#sc-
32931,] using chemiluminescence as described by [32].
The blots were visualized by incubation with SuperSignal
West Femto Substrate (Thermo Scientific, Rockford, IL)
in the Fusion FX Gel Documentation system (Vilber
Lourmat, Germany). The signal intensities were deter-
mined using the Fusion-CAPT software (Vilber Lourmat,
Montreal Biotech, Dorval, PQ), and Dlc1 protein expres-
sion levels were determined as a ratio to β-actin (1:10,000
dilution, Sigma, St. Louis, MO).
Confocal microscopy
The media was aspirated from each well of the 8-well
chamber slide and the acinar structures fixed with 4 %
paraformaldehyde at room temperature for 20 min. In
some experiments, acinar structures were treated with
250 μM etoposide (Sigma) for 24 h and then fixed. Once
fixed, the wells were rinsed with PBS and permeabilization
was carried out using 0.5 % Triton X-100 for 10 min
at 4 °C. Then they were rinsed thrice with PBS containing
100 mM glycine. The acinar structures were blocked with
IF buffer [34, 37] (130 mM NaCl, 7 mM Na2HPO4,
3.5 mM NaH2PO4, 0.1 % BSA, 0.2 % Triton X-100 and
0.05 % Tween-20) containing 10 % goat serum [37] for
60 min. Structures were then incubated with primary
antibodies specific for β-catenin (BD Biosciences, San
Jose, USA Cat# 610153), α-6 integrin (Millipore, Cat#
MAB1378) and E-cadherin (BD Biosciences, San Jose,
USA, Cat# 610181) cleaved caspase-3 (Cell signaling tech-
nology, Beverly, MA,) overnight at 4 °C. The acinar struc-
tures were then carefully rinsed 2–3 times for 20 min with
IF buffer at room temperature with gentle rocking followed
by incubation with fluorescent-tagged secondary antibodies
conjugated to FITC or PE (BD Biosciences) (1:300) for 1 h
at room temperature. After rinsing the structures with one
wash of IF buffer and 2–3 washes of PBS, the nuclei were
counterstained with To-Pro-3 (5 μM, Molecular Probes,
Eugene, OR)or DAPI (4′,6-diamidino-2-phenylindole)
(Sigma). After a final rinse in PBS for 5 min at room
temperature, the chamber slide was mounted with a glass
cover slip using Prolong Anti-fade reagent (Life Technolo-
gies, Burlington, ON) and allowed to dry overnight at room
temperature. Microscopic analysis was performed using a
FV500 laser scanning confocal microscopy system
(Olympus) and Z stacking function was used for serial con-
focal sectioning of the acinar structures at 2 μm intervals.
Images were acquired using Fluoview software [38].
Fig. 2 Terminal end bud deformities in Dlc1gt\+ mammary glands. a & c Representative images of the fourth inguinal mammary gland whole
mounts from 10-week-old virgin female wild type (a & c) and Dlc1gt/+ (b & d) mice stained with carmine alum. Scale bar 200 μm. e Bar graph
quantifying the number of deformed TEBs comparing distal or proximal regions relative to the central lymph node. Data represent the mean ±
SD of 5 different glands (N = 5) from 5 different mice studied for each group. **p < 0.01, *p < 0.05
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Fig. 3 Mammary ductal thickening in Dlcgt/+ mice. a & b Representative images of the fourth inguinal mammary gland whole mounts from
10-week-old virgin female wild type mice (a) and heterozygous Dlc1gt/+ gene trapped mice (b). Red arrows indicate ductal thickening. Scale bar,
2 mm. c Quantification of ductal thickness. The bar graph shows that the average width of ductul branches from the proximal region compared
with the distal region relative to the central lymph node. Data represent the mean ± SD from a total number of 5 different glands (N = 5) from 5
different mice for each group. **p < 0.01, *p < 0.05
Fig. 4 Dlc1gt/+ mice show increased stromal collagen deposition in mammary glands. a–d Histological sections stained with H&E showed a thickened
stromal layer in both the alveolar and ductal structures in the mammary glands from 10-week-old Dlc1gt/+ (b & d) compared with WT mice (a & c). These
figures are representative of a total of 4 different glands (N= 4) from 4 different mice studied for each group. e–h Representative Masson’s trichrome
staining (blue) of mammary glands from 10 week old virgin WT (e & g) and Dlc1gt/+ mice (f & h). The red arrows indicate areas of collagen deposition into
the surrounding stroma. The fourth inguinal mammary glands from 3 different mice from each genotype were studied. Scale bar 100 μm
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Rho activity assay
Primary mammary epithelial cells from WT and Dlc1gt/+
mice were grown to confluency on collagen coated
10 cm cell culture plates. The cells were then serum
starved for 1 h followed by stimulation with 15 % serum
for 5 min. Soon after this stimulation, the cells were
washed twice with ice-cold Tris Buffered Saline (TBS).
The entire procedure was performed in the cold room.
Cold lysis buffer composition, as described by Ren and
Schwartz [39], was added to the cells. The cell lysates
were prepared and analysed for active RhoA by the pull
down assay as described by Ren and Schwartz [39].
Briefly, cells were scraped rapidly to avoid nuclear lysis
and the lysates were transferred to 1.5 ml tubes and
spun at 13,000 g for 10 min at 4 °C. Cleared lysates were
transferred to tubes containing 30 μg of GST-Rhotekin-
Rho binding domain glutathione-Sepharose beads and
rotated at 4 °C for 1 h. The beads were then washed
four times at 5000 rpm (Sorvall Legend Micro21R
centrifuge, Thermoscientific) for 15 s with 600 μl cold
Tris buffer. The beads were then resuspended in SDS
sample buffer containing 40 mM dithiothreitol. Fol-
lowing SDS-PAGE and Western blotting, the mem-
branes were probed with anti-RhoA antibody (Cell
Signaling Technology, Beverly, MA, Cat#2117,). The
signal intensities were determined using the Fusion-
CAPT software (Vilber Lourmat) and active Rho sig-
nal intensity was normalized to total Rho.
Statistical analysis
The two tailed student T-test was used to determine
statistical significance (p < 0.05) using the GraphPad
Prism 4.02 program (San Diego, CA).
Fig. 5 Histological sections of mouse mammary glands stained with cytokeratin lineage markers, cleaved caspase-3 and Ki67. a–b Immunostaining of
the mouse mammary glands with lineage markers cytokeratins 14 (Basal/myoepithelial) and 18 (Luminal) from 10-week old WT mice (a) and Dlc1gt/+
mice (b). Cleaved caspase-3 staining in 10-week old Dlc1gt/+ (d) and WT mice (c). Ki67 staining of mouse mammary glands from WT (e) and Dlc1gt/+
(f). The orange arrows indicate cells with Ki67 positive nuclei. The bar graph is the percentage of Ki67 positive cells (g). Data represent the mean ± SEM
from a total number of 3 different glands (N = 3) from 3 different mice for each group p = 0.2. Scale bar 50 μm
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Results
Heterozygous Dlc1 loss affects mammary gland branching
Previous results had suggested that the chromosome region
8p22, where Dlc1 maps, may contain a haploinsufficient
tumor suppressor gene in breast cancer [1]. Therefore, we
wanted to determine whether heterozygous loss of Dlc1 in a
mouse model would affect mammary gland development.
To do so, we made use of a Dlc1 gene trapped mouse model
that we had previously developed [32]. Although the homo-
zygous Dlc1 gene trapped mice show embryonic lethality,
the heterozygous mice are grossly normal. To evaluate the
effect of heterozygous loss of Dlc1 on mammary gland de-
velopment, we examined whole mount mammary gland
preparations from these mice. On comparing the mammary
glands from the age matched WTand heterozygous Dlc1gt/+
gene-trapped mice, we found that the WT mammary gland
showed regular ductal branching as is observed in virgin
females of the C57BL background [Fig. 1a–d]. As has been
previously reported [40], we also observed limited alveolar
structures or secondary branching from the main ductal
branches in regions proximal and distal to the central lymph
node in WT mammary glands [Fig. 1a and c]. Unlike WT
control mammary glands, Dlc1gt/+ mammary glands showed
increased ductal branching and side branching from the
main ducts [Fig. 1b, d and e]. Furthermore, mammary
glands from Dlc1gt/+ mice also showed a significant increase
in the total number of TEBs or branch points in the region
distal to the central lymph node [Fig. 1f].
Deformity in the terminal end buds or branch points due
to Dlc1 deletion
When the whole mounts were examined closely, we found
branch points/TEB structures with smooth bulbous struc-
tures in WT mice [Fig. 2a and c]. In contrast, the Dlc1gt/+
Fig. 6 Mammary epithelial cells from Dlc1gt/+ mice show defects in acinar lumen formation when grown in Matrigel cultures. a Representative
images of acinar structures formed from mammary epithelial cells from 10 week old wild type (top) and Dlc1gt/+ (lower) mice grown in 3D
Matrigel cultures. Acini are shown at day 12 after plating. Acinar structures were stained with To-Pro-3 and antibodies against α6 integrin (left), or
β-catenin (right). b Acinar structures were stained with E-Cadherin and To-Pro-3 from 10 week old wild type (top) and Dlc1gt/+ (lower). Scale bar,
50 μm. Serial confocal images were taken using Z-stacking function through the middle of the acini. c Quantification of acini showing filled
lumens. Data is the mean ± SD from a total number of 5 different glands (N = 5) from 5 different mice for each. **p < 0.001
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mice displayed more ductal side branching and deformed
or irregular bulbous structures at the branch points [Fig. 2b
and d]. We noted a significant increase in the number of
deformed TEBs and branch points in both the proximal
and distal parts of the glands from the Dlc1gt/+ mice when
compared with the age-matched WT mice [Fig. 2e].
The mammary glands from Dlc1gt/+ mice displayed in-
creased thickening of the ductal branches compared with
WT controls [Fig. 3a and b]. The significant increase in
ductal branch thickening (red arrowheads) in Dlc1gt/+
mice was observed specifically in the proximal part of the
mammary gland, but not in the distal region [Fig. 3c].
We have not observed any evidence of hyperplasia or
spontaneous tumors in the Dlc1gt/+ mice kept for one
year or more.
Heterozygous Dlc1gt/+ gene-trapped mice showed
increased stromal layer thickening surrounding alveolar
and duct structures
Hematoxylin and Eosin stained sections showed the
presence of a thickened stromal layer surrounding both
the alveoli and ducts in Dlc1gt/+ mice compared with
age-matched controls [Fig. 4a–d]. In order to determine
whether this was due to stromal collagen deposition, we
stained sections with Masson’s Trichrome [Fig. 4e–h]. It
was observed that the Dlc1gt/+ mammary gland sections
of both ducts [Fig. 4f] and alveoli [Fig. 4h] had increased
collagen-rich staining (blue colour) in the extracellular
matrix.
Histological sections of mouse mammary glands
were stained with lineage markers cytokeratins 14
(CK-14) and 18 (CK18). We found no visible differ-
ences in the Dlc1gt/+ mice mammary glands com-
pared to the age matched control mice [Fig. 5a and b].
The ducts showed normal myoepithelial or basal (CK14)
and luminal (CK18) epithelial cell organization. We
also could not detect any cleaved caspase-3 staining
in the two genotypes [Fig. 5c and d]. We also quanti-
fied the Ki67 positive cells (orange arrow) in the
histological sections and found no statistically signifi-
cant difference in cells in S-phase between the two
genotypes [Fig. 5e–g].
Fig. 7 Luminal filling of the acinar structures formed from mammary epithelial cells of Dlc1gt/+ mice grown in 3D Matrigel culture is not due to
defects in apoptosis. Representative images of acinar structures from mammary epithelial cells from 10 week old wild type mice (a & e) at days 6
& 12 after culturing in Matrigel or treated with etoposide (b & f) and stained with cleaved caspase-3 antibody and To-Pro-3. Acinar structures of
mammary epithelial cells from Dlc1gt/+ mice at day 6 (c) and day 12 (g) or treated with etoposide (d & h). Scale bar 100 μm
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Loss of Dlc1 affects epithelial cell polarity in mammary
epithelial cells cultured in 3D Matrigel
One potential explanation for the changes in ductal branch-
ing observed in Dlc1gt/- mice is that the polarized architec-
ture of the epithelial cells is compromised. In order to
examine this possibility we isolated mammary epithelial
cells from Dlc1gt/+ and age-matched WT control mice and
cultured them in Matrigel. The cells were allowed to grow
for 10–12 days and then fixed and stained. The acinar
structures were stained with polarity markers α6 integrin
(basolateral marker), β-catenin (cell adhesions) and E-
cadherin (adherent junctions). The mammary epithelial
cells from wild type C57BL mice showed acinar-like
structures with hollow lumen in the 3D Matrigel cultures
[Fig. 6a, upper] with proper distribution of α6 integrin, β-
catenin [Fig. 6a, upper] and E-cadherin [Fig. 6b upper]. In
contrast, we found that Dlc1gt/+ mammary epithelial cells
showed defective acinar morphogenesis with over 70 %
exhibiting filled acinar structures [Fig. 6a, lower; b, lower; c].
One possible reason for the filled acinar structures in
cells from Dlc1gt/+ mice is a defect in apoptosis. To test
this possibility, we stained mammary acinar structures
with an antibody for cleaved capapse-3. Acinar struc-
tures at day 6 did not show positivity for cleaved
caspase-3 [Fig. 7a]. Whereas treatment with etoposide,
to induce apoptosis, showed evidence of caspase-3
Fig. 8 Knockdown of Dlc1 in primary mammary epithelial cells show defects in acinar lumen formation. a–b Merged images showing green
fluorescence protein expressed from the shRNA lentiviral vectors and DAPI (blue) in 3D Matrigel cultures. WT mammary epithelial cells infected
with lentivirus expressing scramble control (a) or Dlc1 shRNA (b). Scale bar 100 μm. c Bar graph showing the percentage of solid acinar structures
after lentivirus infection (p < 0.0001). d Quantitative RT-PCR analysis of Dlc1 mRNA levels following infection with Dlc1 targeting and scrambled
control lentiviruses. Transcript levels were normalized to GAPDH (p = 0.0024). e Immunoblot analysis of Dlc1 protein levels in WT mammary
epithelial cells infected with Dlc1 targeting and scrambled control lentiviruses. Four independent experiments with n = 3 animals in each group
were used in this study
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cleavage [Fig. 7b]. Similarly, the WT cells cultured for
12 days showed no positivity for cleaved caspase-3, but
did after etoposide treatment [Fig. 7e, f]. The acinar
structures from Dlc1gt/+ mammary epithelial cells
showed filled acinar structures at day 6 [Fig. 7c] and at
day 12 [Fig. 7g]. The filled acinar structures from Dlc1gt/
+ mice did not show any cleaved caspase-3 positivity but
did show significant amounts following etoposide treat-
ment [Fig. 7d and h].
To confirm the finding of defective acini in epithelial
cells from Dlc1gt/+ mice, we knocked down Dlc1 expres-
sion using shRNA in primary mouse wild type mammary
epithelial cells using lentivirus[Fig. 8]. Knockdown of
Dlc1 in primary mammary epithelial cells was confirmed
by real time RT-PCR and Western blotting [Fig. 8d and e].
Furthermore, we found that similar to mammary epithelial
cells from Dlc1gt/+ mice, the knockdown of endogenous
Dlc1 expression led to a significant increase in irregular
acinar-like structures with filled lumen compared with
scrambled shRNA control [Fig. 8c].
Primary mammary epithelial cells from heterozygous Dlc1gt/+
gene-trapped mice cells show increased RhoA activity
Next, we wanted to determine whether the loss of one
Dlc1 allele resulted in increased RhoA activity. A Rho-
GTP pull down assay was performed to evaluate the ac-
tive Rho levels in primary mammary epithelial cells. We
found that cells from Dlc1gt/+ mice showed significant
elevation in RhoA activity both before and after stimula-
tion with serum compared with wild type mammary epi-
thelial cells [Fig. 9].
Discussion
It has been previously shown that Rho signalling plays
an important role in controlling mammary ductal mor-
phogenesis [29–31]. Our results showed that heterozy-
gous loss of Dlc1 increases ductal branching. This is in
contrast to what was seen in mice with heterozygous or
homozygous loss of p190B RhoGAP, which resulted in
decreased numbers and rate of ductal outgrowth [29].
This suggests that it is the local temporal control of Rho
activity and not just the increase in Rho activity that is
critical for disrupting ductal morphogenesis. For ex-
ample, p190B RhoGAP plays an important role in cyto-
kinesis by controlling Rho activity at the cleavage furrow
[41] whereas, Dlc1 controls focal adhesion dynamics and
cell motility [32, 42–44]. Another study using Net1 Rho-
GEF knockout mice showed delayed ductal extension
and reduced ductal branching in the mammary gland,
which supports the contention that precise control of
RhoA activation is essential for proper mammary mor-
phogenesis [45].
Mouse strain differences in mammary ductal side
branching pattern is dictated by the stromal compartment
Fig. 9 Rho Activity assay in primary mouse mammary epithelial cells. a Representative western blot showing the activation of RhoA in primary
mammary epithelial cells plus or minus serum addition as described in the materials and methods section. b Bar graph showing the active RhoA
levels determined by normalizing the amount of RBD-bound Rho to the total RhoA in whole cell lysates. Data is represented as the mean ± SEM
from a total of 6 independent experiments. Statistical analyses were performed using student T test. *p < 0.05; **p < 0.01. [WT - FBS vs WT+FBS,
p = 0.04; Dlc1gt/+-FBS vs Dlc1gt/++FBS, p = 0.022; WT-FBS vs Dlc1gt/+ -FBS, p = 0.021; WT+FBS vs Dlc1gt/++FBS, p = 0.0085]
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[46]. Although the heterozygous loss of Dlc1 would be
found in both the stromal and epithelial layers, we have
shown that this effect is at least partially due to defects in
epithelial cell polarity, as revealed in 3D cultures. In this
study, we also found increased stromal collagen deposition
surrounding the ducts and alveolar structures. Previously,
it was shown that targeted activation of the Rho effector
ROCK2 kinase to mouse skin resulted in increased colla-
gen deposition [47]. Whether the increased collagen de-
position is due to altered Rho activity in stromal or
epithelial cells will be the subject of future experiments.
One of the most intriguing findings of our work is the
filling up of the lumen when mammary epithelial cells
from the Dlc1gt/+ mice were placed in 3D Matrigel cul-
tures. This phenotype was also seen when Dlc1 was
knocked down in wild type mammary epithelial cells. Our
results indicate that this phenotype is not due to a defect
in apoptosis, as no cleaved caspase 3 was detected during
lumen formation in wild type or Dlc1gt/+ 3D cultures. This
is in agreement with other studies in which no induction
of apoptosis was seen during lumen formation in primary
mouse mammary epithelial cells [48]. Although lumen fill-
ing is an extreme phenotype, the mammary ducts did not
show evidence of hyperplasia of epithelial cells lining the
ducts or acini. This may indicate that when Dlc1gt/+ mam-
mary epithelial cells are surrounded by the normal stromal
microenvironment, this phenotype is suppressed [49, 50].
Several studies of breast cancer have found that
chromosomal region 8p22, where Dlc1 maps, is a site
of frequent deletions without a loss of heterozygosity,
suggesting the location of a haploinsufficient tumor
suppressor(s) [1, 51, 52]. Xue et al. have suggested
that Dlc1 and other putative tumor suppressor genes
on chromosome region 8p22 are haploinsufficient,
since they showed heterozygous deletion and reduced
expression in tumors, but not total loss of expression
[7]. Our results showing that heterozygous loss of
Dlc1 can alter mammary morphogenesis and epithelial
cell polarity in 3D cultures, suggests that Dlc1 is
haploinsufficient for these processes. Previously, we
showed that serum free mouse embryo cells homozy-
gous for Dlc1gt/gt showed a significant increase in
RhoA activity compared with wild type cells, suggest-
ing that increased RhoA activity is responsible for the
loss of polarity [32]. This also suggests that Dlc1 hap-
loinsufficiency may contribute to tumor progression
by disrupting epithelial polarity along with oncogene
activation. Future studies to address this hypothesis
are now in progress.
Conclusions
This study shows that decreased Dlc1 expression can
disrupt mammary epithelial cell polarization, which re-
sults in increased mammary ductal branching. This
suggests that normally Dlc1 plays a role in maintaining
epithelial cell polarity and that it is haploinsufficient.
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